Bank of New York Mellon
IMRX icon

Bank of New York Mellon’s Immuneering IMRX Stock Holding History

Bank of New York Mellon’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$659K Buy
+132,004
New +$668K ﹤0.01% 3604
2024
Q2 		– Sell
-53,778
Closed -$155K – 4200
2024
Q1 		$155K Sell
53,778
-10,251
-16% -$57.4K ﹤0.01% 3983
2023
Q4 		$471K Buy
64,029
+6,343
+11% +$42.3K ﹤0.01% 3589
2023
Q3 		$443K Buy
57,686
+245
+0.4% +$2.25K ﹤0.01% 3610
2023
Q2 		$582K Buy
+57,441
New +$552K ﹤0.01% 3503
2022
Q2 		– Sell
-48,431
Closed -$314K – 4652
2022
Q1 		$314K Buy
48,431
+24,556
+103% +$236K ﹤0.01% 3993
2021
Q4 		$386K Buy
23,875
+3,276
+16% +$79.7K ﹤0.01% 3951
2021
Q3 		$547K Buy
+20,599
New +$554K ﹤0.01% 3764

Other funds holding IMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Bank of New York Mellon's IMRX Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Immuneering (IMRX) in Q2 2026: 132,004 shares worth $659K. The stake represents ﹤0.01% of the portfolio and ranks #3604 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in IMRX as recently as Q1 2024.

Bank of New York Mellon first reported a position in IMRX in Q3 2021 and has held it in 8 quarters since. 50 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Bank of New York Mellon held 132,004 shares of Immuneering worth $659K as of Q2 2026.
  • Immuneering was a new Bank of New York Mellon position in Q2 2026.
  • Immuneering made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3604 holding.
  • Bank of New York Mellon first reported a position in Immuneering in Q3 2021 and has held it in 8 quarters since.
  • 50 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.